ATM inhibitor-1 interferes with DNA damage response and repair processes, enhancing the sensitivity of cancer cells. It targets ATM, ATM, DNAPK, mTOR, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.